1. Home
  2. RARE
  3. RARE News

Latest Ultragenyx Pharmaceutical Inc. (RARE) News on July 27, 2024

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

a day ago

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
RARE

GlobeNewswire

3 days ago

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
RARE

Investor's Business Daily

4 days ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

7 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
RARE

Zacks

8 days ago

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans

RARE

MT Newswires

9 days ago

Ultragenyx Reports 'Successful' End-of-Phase 2 FDA Meeting For Angelman Syndrome Program

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
RARE

GlobeNewswire

9 days ago

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

a month ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE

MT Newswires

a month ago

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating

RARE

MT Newswires

a month ago

Ultragenyx Pharmaceutical Prices $350 Million Offering

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
RARE

GlobeNewswire

a month ago

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
RARE

Zacks

a month ago

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
RARE

Simply Wall St.

a month ago

Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...
RARE

GuruFocus.com

a month ago

Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...

RARE

MT Newswires

a month ago

Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025

RARE

MT Newswires

a month ago

Ultragenyx Pharmaceutical Launches Equity Offering

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
RARE

GlobeNewswire

a month ago

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

a month ago

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

RARE

MT Newswires

a month ago

Update: Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate

Ultragenyx (RARE) Posts New Data From Bone Disease Study
RARE

Zacks

a month ago

Ultragenyx (RARE) Posts New Data From Bone Disease Study

RARE

MT Newswires

a month ago

Sector Update: Health Care

Ultragenyx, Mereo drug reduces fractures in bone disorder study
RARE

BioPharma Dive

a month ago

Ultragenyx, Mereo drug reduces fractures in bone disorder study

RARE

MT Newswires

a month ago

Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
RARE

GlobeNewswire

a month ago

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

RARE

MT Newswires

2 months ago

Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
RARE

GlobeNewswire

2 months ago

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

RARE

MT Newswires

2 months ago

Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
RARE

Zacks

2 months ago

Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study

RARE

MT Newswires

2 months ago

Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating

RARE

MT Newswires

2 months ago

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
RARE

GlobeNewswire

2 months ago

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
RARE

Benzinga

2 months ago

Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

2 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
RARE

GlobeNewswire

3 months ago

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
RARE

Insider Monkey

3 months ago

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript

Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
RARE

Simply Wall St.

3 months ago

Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results

RARE

GuruFocus.com

3 months ago

Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
RARE

Zacks

3 months ago

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
RARE

GuruFocus.com

3 months ago

Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...

RARE

Associated Press Finance

3 months ago

Ultragenyx: Q1 Earnings Snapshot

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

3 months ago

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
RARE

GlobeNewswire

3 months ago

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
RARE

GlobeNewswire

3 months ago

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
RARE

GlobeNewswire

3 months ago

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

3 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
RARE

Zacks

3 months ago

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Ultragenyx says Angelman therapy is working, but safety questions remain
RARE

BioPharma Dive

3 months ago

Ultragenyx says Angelman therapy is working, but safety questions remain

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
RARE

GlobeNewswire

3 months ago

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
RARE

GlobeNewswire

3 months ago

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
RARE

GlobeNewswire

3 months ago

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

4 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 NASDAQ Stocks with Biggest Upside
RARE

Insider Monkey

4 months ago

10 NASDAQ Stocks with Biggest Upside

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
RARE

GuruFocus.com

4 months ago

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...

Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
RARE

GuruFocus.com

5 months ago

Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)

10 Biotech Stocks with Huge Potential
RARE

Insider Monkey

5 months ago

10 Biotech Stocks with Huge Potential

Ultragenyx to Participate at Investor Conferences in March
RARE

GlobeNewswire

5 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARE

GlobeNewswire

5 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
RARE

Simply Wall St.

5 months ago

Ultragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
RARE

Insider Monkey

5 months ago

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript

RARE

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
RARE

Zacks

5 months ago

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

RARE

Associated Press Finance

5 months ago

Ultragenyx: Q4 Earnings Snapshot

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
RARE

GlobeNewswire

5 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

15 Best Strong Buy Stocks To Invest In
RARE

Insider Monkey

5 months ago

15 Best Strong Buy Stocks To Invest In

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
RARE

GlobeNewswire

6 months ago

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
RARE

GlobeNewswire

6 months ago

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
RARE

GlobeNewswire

6 months ago

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

UMC vs. CRUS: Which Stock Should Value Investors Buy Now?
RARE

Zacks

6 months ago

UMC vs. CRUS: Which Stock Should Value Investors Buy Now?

Carvana Accelerates Car Buying with Same-Day Delivery in San Antonio
RARE

Business Wire

6 months ago

Carvana Accelerates Car Buying with Same-Day Delivery in San Antonio

Why the Market Dipped But Wingstop (WING) Gained Today
RARE

Zacks

6 months ago

Why the Market Dipped But Wingstop (WING) Gained Today

Why Polaris (PII) Shares Are Falling Today
RARE

StockStory

6 months ago

Why Polaris (PII) Shares Are Falling Today

DISH MEDIA ADOPTS UNIFIED ID 2.0, ENHANCING FIRST-PARTY DATA AUDIENCES FOR ADVERTISERS ACROSS DISH TV AND SLING TV
RARE

PR Newswire

6 months ago

DISH MEDIA ADOPTS UNIFIED ID 2.0, ENHANCING FIRST-PARTY DATA AUDIENCES FOR ADVERTISERS ACROSS DISH TV AND SLING TV

15 Best Annual Dividend Stocks To Buy Now
RARE

Insider Monkey

6 months ago

15 Best Annual Dividend Stocks To Buy Now

Rithm Capital Corp. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
RARE

Business Wire

6 months ago

Rithm Capital Corp. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Nippon Steel says Japan's 3 megabanks plan $16 billion loan for U.S. Steel acquisition
RARE

Reuters

6 months ago

Nippon Steel says Japan's 3 megabanks plan $16 billion loan for U.S. Steel acquisition

Rithm Capital Corp. Announces Treatment of 2023 Taxable Dividends
RARE

Business Wire

6 months ago

Rithm Capital Corp. Announces Treatment of 2023 Taxable Dividends

Things to Note Before Post Holdings' (POST) Q1 Earnings
RARE

Zacks

6 months ago

Things to Note Before Post Holdings' (POST) Q1 Earnings

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis
RARE

GlobeNewswire

6 months ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

Energy Transfer (ET) Raises Quarterly Distribution Rate by 0.8%
RARE

Zacks

6 months ago

Energy Transfer (ET) Raises Quarterly Distribution Rate by 0.8%

How a 'complex' Medicare Advantage market left Humana scrambling to start 2024
RARE

Yahoo Finance

6 months ago

How a 'complex' Medicare Advantage market left Humana scrambling to start 2024

1 Stock I Wouldn't Touch With a 10-Foot Pole
RARE

Motley Fool

6 months ago

1 Stock I Wouldn't Touch With a 10-Foot Pole

Got $1,000? 3 Energy Stocks to Buy and Hold Forever
RARE

Motley Fool

6 months ago

Got $1,000? 3 Energy Stocks to Buy and Hold Forever

Badger Meter, Inc. (NYSE:BMI) Q4 2023 Earnings Call Transcript
RARE

Insider Monkey

6 months ago

Badger Meter, Inc. (NYSE:BMI) Q4 2023 Earnings Call Transcript

5 Phenomenal Stocks I Just Bought That You Should Consider Too
RARE

Motley Fool

6 months ago

5 Phenomenal Stocks I Just Bought That You Should Consider Too

Copa Holdings (CPA) Stock Moves -0.07%: What You Should Know
RARE

Zacks

6 months ago

Copa Holdings (CPA) Stock Moves -0.07%: What You Should Know

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
RARE

GlobeNewswire

6 months ago

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Here is What to Know Beyond Why Copa Holdings, S.A. (CPA) is a Trending Stock
RARE

Zacks

6 months ago

Here is What to Know Beyond Why Copa Holdings, S.A. (CPA) is a Trending Stock

Sensata Technologies Board Approves Q1 Dividend of $0.12 Per Share
RARE

Business Wire

6 months ago

Sensata Technologies Board Approves Q1 Dividend of $0.12 Per Share

Cadence Bank Announces Increase in Quarterly Common Dividend; Declares Preferred Dividend
RARE

PR Newswire

6 months ago

Cadence Bank Announces Increase in Quarterly Common Dividend; Declares Preferred Dividend

The Boston Beer Company’s Slingers Signature Cocktails™ Enters Phase Two of Test Launch, Expanding Distribution from 3 to 19 Wholesalers
RARE

GlobeNewswire

6 months ago

The Boston Beer Company’s Slingers Signature Cocktails™ Enters Phase Two of Test Launch, Expanding Distribution from 3 to 19 Wholesalers

Toll Brothers New Home Community, Bowes Creek Country Club, Offers Final Selection of Home Sites in Popular Chicago Suburb
RARE

GlobeNewswire

6 months ago

Toll Brothers New Home Community, Bowes Creek Country Club, Offers Final Selection of Home Sites in Popular Chicago Suburb

Here is What to Know Beyond Why Toll Brothers Inc. (TOL) is a Trending Stock
RARE

Zacks

6 months ago

Here is What to Know Beyond Why Toll Brothers Inc. (TOL) is a Trending Stock

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider
RARE

Zacks

6 months ago

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider

Here's Why Gap (GPS) Stock Appears a Promising Pick Now
RARE

Zacks

6 months ago

Here's Why Gap (GPS) Stock Appears a Promising Pick Now

NICE Actimize Positioned as Overall Leader in the 2023 Quadrant Knowledge Communications Surveillance Report
RARE

Business Wire

6 months ago

NICE Actimize Positioned as Overall Leader in the 2023 Quadrant Knowledge Communications Surveillance Report

Spotting Winners: Costco (NASDAQ:COST) And Large-format Grocery & General Merchandise Retailer Stocks In Q3
RARE

StockStory

6 months ago

Spotting Winners: Costco (NASDAQ:COST) And Large-format Grocery & General Merchandise Retailer Stocks In Q3

Axcelis Technologies, Inc. (ACLS) Is a Trending Stock: Facts to Know Before Betting on It
RARE

Zacks

6 months ago

Axcelis Technologies, Inc. (ACLS) Is a Trending Stock: Facts to Know Before Betting on It

Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years
RARE

Simply Wall St.

6 months ago

Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years

Former Upscale Hotelier Tries Comeback With New Brand Aimed at Gen Z
RARE

The Wall Street Journal

6 months ago

Former Upscale Hotelier Tries Comeback With New Brand Aimed at Gen Z

Investors in SPS Commerce (NASDAQ:SPSC) have seen fantastic returns of 316% over the past five years
RARE

Simply Wall St.

6 months ago

Investors in SPS Commerce (NASDAQ:SPSC) have seen fantastic returns of 316% over the past five years

Share on Social Networks: